

Serum Vascular Endothelial Growth Factor in Ovarian Cancer

Thesis

*Submitted for partial fulfillment of
M.D Degree in Obstetrics and Gynecology*

By

Ghada Yehia Ahmed Kassim

*M.B., B.Ch., M.Sc. Obstetrics and Gynecology
Ain Shams University*

Supervised By

Prof. Mohamed Abd El-Hamid Yehia

*Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University*

Prof. Maged Ramadan Abu-Seeda

*Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University*

Prof. Khaled Kamal Ali

*Professor of Obstetrics and Gynecology
Faculty of Medicine – Ain Shams University*

Prof. Ismail Khalil El-Lamie

*Professor of Obstetrics and Gynecology
Faculty of Medicine - Ain Shams University*

Prof. Mahmoud Ismail Hassan

*Professor of Biochemistry & Molecular Biology
Faculty of Medicine – Ain Shams University*

**Faculty of Medicine
Ain Shams University
2012**

أهمية قياس مستوى عامل نمو بطانة الأوعية الدموية في مصل الدم في حالات أورام المبيض الخبیثة

رساله

توطئه للحصول على درجة الدكتوراه
فی أمراض النساء والتوليد

مقدمه من

الطالبة/ غادة يحيى أحمد قاسم
ماجستير أمراض النساء والتوليد
جامعة عين شمس

تحت اشراف

الاستاذ الدكتور/ محمد عبد الحميد يحيى
أستاذ أمراض النساء والتوليد
كلية الطب – جامعة عين شمس

الأستاذ الدكتور/ ماجد رمضان أبو سعده
أستاذ أمراض النساء والتوليد
كلية الطب جامعة عين شمس

الأستاذ الدكتور/ خالد كمال على
أستاذ أمراض النساء والتوليد
كلية الطب جامعة عين شمس

الأستاذ الدكتور/ إسماعيل خليل اللمعى
أستاذ أمراض النساء والتوليد
كلية الطب جامعة عين شمس

الاستاذ الدكتور/ محمود إسماعيل حسن
أستاذ الكيمياء الحيوية والبيولوجيا الجزيئية
كلية الطب جامعة عين شمس
كلية الطب
جامعة عين شمس

2012

Acknowledgement

I would like to express my sincere tanks and iam greatly honored for Prof. Mohamed Abd El-Hamid Yehia, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University for supervising this work.

I would like also to extend my sincere appreciation and iam extremely grateful to Prof. Maged Ramadan Abu-Seeda, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University for supervising this work.

I would like also to express my deepest gratitude to Prof. Khaled Kamal Ali, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University, for his continuous encouragement and guidance to accomplish this work.

I gratefully acknowledge the support and assistance of Prof. Ismail Khalil El-Lamie, Professor of Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University to finish this work.

I would like to express my thanks and appreciation to the soul of Prof. Mahmoud Ismail Hassan, The Head of Oncology Diagnostic Unit & Professor of Biochemistry

& Molecular Biology, Faculty of Medicine – Ain Shams University .

I would like also to acknowledge the valuable help, effort and meticulous revision of this work by Dr. Adel Shafik Salah El-Din, Lecturer in Obstetrics and Gynecology, Faculty of Medicine – Ain Shams University.

List of Contents

Title	Page No.
Introduction	1
Aim of the work	2
<u>Review of Literature</u>	
• Chapter (1) Biology of VEGF	3
o Structure of VEGF	3
o VEGF receptors	7
o Biological actions of VEGF	13
o Regulation of VEGF	23
• Chapter (2) Physiological roles of VEGF	31
o Role of VEGF in adult female	31
o Role of VEGF in ovarian physiology.....	32
• Chapter (3) Role VEGF in pathogenesis of ovarian carcinoma.....	38
o VEGF expression in ovarian carcinoma.....	38
o Role of VEGF in tumor growth	39
o Role of VEGF in ovarian cancer angiogenesis	44
o Regulation of VEGF in tumor cells	47
o Role of VEGF in the pathogenesis of ascites	48
o Role of VEGF in impaired host anti-tumor immune response	51
o Role of VEGF in tumor metastasis	53
o Prognostic implications of VEGF in ovarian cancer.....	57
• Chapter (4) Anti-VEGF therapy in ovarian carcinoma.....	63
o Rational for angiogenesis targeted therapy.....	63
o Combination of anti-angiogenic therapy with chemotherapy	65
o Therapeutic strategies for inhibiting VEGF	66
o Toxicity with VEGF inhibitors	75
o Metronomic chemotherapy and VEGF inhibitors.....	78
Patients and Methods	80
Results	95
Discussion.....	127
Summary.....	146
Conclusions	149
Recommendations.....	150
References.....	151
Arabic Summary	---

List of Tables

Table No.	Title	Page No.
Table (1):	Hormones and their effect on angiogenesis and VEGF expression.....	30
Table (2):	Ongoing trials with multitargeted tyrosine kinase inhibitors in ovarian cancer.....	73
Table (3):	Descriptive statistics – numerical data.	97
Table (4):	Descriptive statistics – categorical data.	98
Table (5):	Preoperative serum VEGF level according to age category.....	106
Table (6):	Preoperative serum VEGF level according to histopathologic type.	106
Table (7):	Preoperative serum VEGF level according to FIGO stage.....	107
Table (8):	Preoperative serum VEGF level according to tumor grade.	108
Table (9):	Preoperative serum VEGF level according to presence of ascites.....	109
Table (10):	Preoperative SVEGF level according to presence of omental or lymph node metastasis, disease laterality, state of cytoreduction, and disease state at one-year.....	111
Table (11):	Serum VEGF levels at various follow-up times.....	115
Table (12):	Comparison of serum VEGF levels at various follow-up times in patients with recurrent disease.....	117
Table (13):	Comparison of SVEGF levels at various follow-up times in patients with no recurrence.....	118
Table (14):	Serum VEGF levels at various follow-up times in patients with recurrence versus those without recurrence.....	119
Table (15):	Correlation between serum VEGF levels and CA125 levels at various follow-up times.....	121

List of Figures

Figure No.	Title	Page No.
Figure (1):	Structural motifs of VEGF exonic regions in the cDNA that encodes VEGF/ VPF products	4
Figure (2):	Signal transduction and biological processes mediated by VEGFRs and various therapeutic strategies to inhibit VEGF signaling.....	11
Figure (3):	The VEGF receptor family.....	13
Figure (4):	Multiple functions of VEGF.....	17
Figure (5):	Angiogenesis in cancer development, growth, and metastasis.....	46
Figure (6):	Icon-6.....	70
Figure (7):	Test Principle.....	87
Figure (8):	Reconstitution and Dilution of test standard.....	88
Figure (9):	Standard curve	89
Figure (10):	Test Procedure summary	91
Figure (11):	Age distribution.....	100
Figure (12):	Histopathologic type.....	100
Figure (13):	FIGO class.....	101
Figure (14):	Tumor grade.	101
Figure (15):	Presence of ascites.	102
Figure (16):	Presence of omental metastasis.	102
Figure (17):	Presence of lymph node metastasis.....	103
Figure (18):	Disease laterality.....	103
Figure (19):	State of cytoreduction.....	104
Figure (20):	State of the patient 3 months.....	104
Figure (21):	Disease state at 12 months.....	105
Figure (22):	Preoperative SVEGF level according to age category.....	106
Figure (23):	Preoperative SVEGF level according to histopathologic type.....	107
Figure (24):	Preoperative SVEGF level according to FIGO stage.....	108
Figure (25):	Preoperative SVEGF level according to tumor grade.....	109
Figure (26):	Preoperative SVEGF level according to presence of ascites.....	110
Figure (27):	Preoperative SVEGF level according to presence of omental metastasis.....	112
Figure (28):	Preoperative SVEGF level according to presence of lymph node metastasis.....	112

Figure (29):	Preoperative SVEGF level according to bilaterality of disease.....	113
Figure (30):	Preoperative SVEGF level according to state of cytoreduction.....	113
Figure (31):	Preoperative SVEGF level according to disease state at one year	114
Figure (32):	SVEGF level at various follow-up times.....	116
Figure (33):	SVEGF levels at various follow-up times in patients with recurrence and those without recurrence at 1 year.	120
Figure (34):	Scatter plot for preoperative SVEGF and CA125 levels.....	122
Figure (35):	Scatter plot for serum VEGF and CA125 levels at 3 months after operation.....	122
Figure (36):	Scatter plot for SVEGF and CA125 levels at 6 months after operation.	123
Figure (37):	Scatter plot for SVEGF and CA125 levels at 12 months after operation.	123
Figure (38):	Receiver-operating characteristic curve (ROC) curve for prediction of state of cytoreduction using preoperative serum VEGF level.....	124
Figure (39):	Receiver-operating characteristic curve (ROC) curve for prediction of one-year recurrence using preoperative serum VEGF level.....	124

List of Abbreviations

AP-1.....	Activator protein-1 (a transcription factor that regulates gene expression in response to cytokines and growth factors)
APC	antigen presenting cells
BcL	B-cell lymphoma/ leukemia
bFGF.....	Basic fibroblast growth factor
COX.....	Cyclooxygenase
DC	Dendritic cells
EGF	Epidermal growth factor
EOC.....	Epithelial ovarian Cancer
ER.....	Estrogen receptor
Ets.....	E-twenty six transcription factors.
Flt-1	Fms-like tyrosin kinase.
HER-2.....	Human epidermal growth factor receptor-2
HIF.....	Hypoxia inducible factor
HRE	Hyoxia response element
HRP	Horseradish peroxidase.
IGF.....	Insulin like growth factor
IL	Interleukin
KDR/FLK	Kinase insert domain receptor / fetal liver kinase.
KGF	Keratinocyte growth factor
Mabs	Monoclonal antibodies
MMP.....	Matrix metallo-proteinase
MVD.....	Mean vascular density
NO	Nitric oxide
NSAID	Nonsteroidal anti-inflammatory drugs
OHSS.....	Ovarian hyperstimulaiton syndrome
PA.....	Plasminogen activators
PAI.....	Plasminogen activator inhibitor
PDGF.....	Platelet derived growth factor

List of Abbreviations (Cont...)

PDGFR	Platelet derived growth factor receptor
PFS	Progression – free survival
PG	Prostaglandin
PLGF	Placental growth factor
RECIST.....	Response Evaluation Criteria in Solid Tumors
RTKIs	Receptor tyrosin kinase inhibitors
sVEGFR.....	Soluble vascular endothelial growth factor receptor
TGF	Transforming growth factor
TMB	Tetramethyl-benzidine substrate
TNF	Tumor necrosis factor
VEGF.....	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VHL.....	Von Hippel-Lindau
VPF.....	Vascular permeability factor
VVO	vesiculo-vacular organelle

Introduction

Ovarian cancer is the leading cause of mortality in gynecologic malignancies and the fifth most common cause of death among all malignancies in women. The patient's best chance for prolonged survival is provided through complete resection of all macroscopic disease. The prognosis is worse if the patients have 2cm or larger residual tumor after primary cytoreductive surgery. For this reason, the prediction of optimal resectability is important (*Saygili et al., 2002*).

Angiogenesis is an essential requirement for tumor growth and metastasis. Without angiogenesis, tumors grow as in situ and will not expand beyond 2-3mm in diameter. VEGF is the most important angiogenic factor (*Shen et al., 2000*).

VEGF is crucially involved in various steps of ovarian carcinogenesis. VEGF expression as well as serum levels were shown to be associated with dismal prognosis of ovarian cancer (Shortened disease – free and overall survival) (*Hefler et al., 2006*).

Currently, angiogenesis appears to be the most promising therapeutic target for ovarian cancer and large phase III trials with anti angiogenic therapeutics are conducted world wide (*Mahner et al., 2010*).

Aim of the Work

- Evaluation of preoperative serum VEGF levels in ovarian carcinoma in relation to various clinical, surgical and pathological variables (age, histopathological type, stage, grade, omental and L.N metastasis, presence of ascites, level of cytoreduction and recurrence).
- Follow up of cases of ovarian cancer with serial evaluations of serum VEGF, 3,6 and 12 months postoperatively.
- Correlation between serum VEGF and CA125 levels.

Chapter (1)

Biology of Vascular Endothelial Growth Factor

Structure of VEGF:

Vascular endothelial growth factor (VEGF) is a disulfide-linked, 34-45 KD homodimeric glycoprotein expressed by a wide variety of normal and transformed cells. Alternatively known as vascular permeability factor (VPF), VEGF was originally noted for the ability to increase microvascular permeability, and subsequently for the capacity to act as a selective endothelial mitogen (*Nowak et al., 2008*).

VEGF/VPF is a basic, heparin binding, glycoprotein, which binds specifically to receptors on endothelial cells. It has specific mitogenic activity on endothelial cells, and it is apparently devoid of mitogenic activity for other cell types (*Woolard et al., 2009*).

Members of the VEGF family include VEGF-A (hereafter VEGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E (a virally encoded protein) and placental growth factor (PlGF), all showing various degrees of homology with VEGF (*Girling and Rogers, 2009*).

The most significant of the VEGF family is VEGF-A that is produced in five isoforms, generated by alternative splicing of the VEGF-A gene (*Fraser, 2006*).

The isoforms are composed of 206-, 189-, 165-, 145-, and 121-amino acid residues (fig. 1). The shorter isoforms, VEGF 145 and VEGF 121, are acidic, do not bind heparin, and are secreted peptides that may act as diffusible agents. The longer isoforms, VEGF-189 and VEGF-206 are basic, with a high affinity for heparin, and remain sequestered in the extra cellular matrix, presumably bound to heparan sulfate proteoglycans. VEGF-165 which is the predominant molecular species is in part secreted and in part matrix bound (*Ferrara, 2004*).




Fig. (1): Structural motifs of VEGF exonic regions in the cDNA that encodes VEGF/ VPF products, full-length form VEGF206, and alternatively spliced transcripts encoding 121-, 145-, 165, and 189-aa VEGF isoforms (*Geva and Jaffe, 2000*).

The various isoforms not only differ in efficiency of secretion and affinity for heparin, but also in the relative potency of vascular permeabilizing and mitogenic activities (*Bastide et al., 2008*).

The human VEGF-A gene has been localized to chromosome 6p21.3, composed of eight exons, separated by seven introns (*Geva et al., 2000*).

The primary VEGF-A transcript derives from a single VEGF-A gene, coding for eight exons. The amino acids encoded by exons 1 to 5 and 8 are conserved in all isoforms, whereas variable alternative splicing occurs in exons 6 and 7, which encode two distinct heparin-binding domains. The presence or absence of these domains influences solubility and receptor binding. The heparin-binding domain encoded by exon-6 determines binding to the extra-cellular matrix, and therefore isoforms containing this domain (VEGF-A 189 and VEGF-A 206) are bound tightly to cell surface heparin-containing proteoglycans in the extra-cellular matrix, whereas those lacking the domain are diffusible. VEGF-A 165, which contains only one heparin-binding region encoded by exon7, is moderately diffusible, and VEGF-A 121, which lacks the domains encoded by both exons 6 and 7 is highly diffusible (*Hoeben et al., 2004*).

Plasmin liberates the heparin binding forms of VEGF that can bind to cell-surface and extracellular